We believe that ongoing research into disease states and treatments is a vital part of improving our patients’ well-being. Research enables new cures and better treatments. We are committed to participating in cutting-edge research, allowing our patients to have access to the latest treatment options and furthering scientific development.

We have included brief summaries on clinical research trials which are currently enrolling.  We have grouped these trials by diagnosis, ranging from macular degeneration and diabetic macular edema to uveitis and ocular melanoma.

For more information on any of the studies, please contact the research department anytime with your specific questions 720-420-3265

Study Summaries

We are currently enrolling patients for these clinical trials.

Dry AMD

Toga TOGA-01 (A Randomized, Double Masked, Placebo Controlled Study Evaluating Oracea® In Subjects with Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration) (University of Virginia)

In this study, patients will take an oral medication daily for 24 months. This is a 25 month study at Red Rocks Medical Center or the Porter Hospital Campus.

Uveitis

Eyegate EGP-437-006 (A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled, Phase 3 Clinical Trial Designed To Evaluate The Safety And Efficacy Of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared To Prednisolone Acetate Ophthalmic Suspension (1%) In Patients with Non-Infectious Anterior Segment Uveitis) (Eyegate)

In this study, patients will receive three treatments with iontophoresis over two weeks and daily eye drops for one month. This is a two month study at Red Rocks Medical Center.

Peachtree CLS1001-301:  A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects with Macular Edema associated with Non-Infectious Uveitis

In this study, patients will receive two suprachoroidal injections of CLS-TA or sham injections approximately 12 weeks apart.  This is a 27 week study consisting of 8 visits at the Red Rocks Medical Center.

Uveal Melanoma

Iconic IT-003 (A Phase 1, Opne-Label, Multicenter Study Evaluating the Safety and Tolerability, Biologic Activity, Pharmacodynamics, and Pharmacokinetics of Single and Repeated Escalating Intravitreal Does of ICON-1 in Patients with Uveal Melanoma Who are Planned to Undergo Enucleation) (Iconic Therapeutics)

In this study, patients will receive intravitreal injections for up to 3 weeks.  This is an 8 week study at the Porter Hospital Campus.

Wet AMD

Ladder GX28228 (A Phase II, Multicenter, Randomized, Active Treatment-Controlled Study Of The Efficacy And Safety Of The Ranibizumab Port Delivery System For Sustained Delivery Of Ranibizumab In Patients With Subfoveal Neovascular Age-Related Macular Degeneration) (Genentech)

In this study, patients will receive either a refillable implant or monthly intravitreal injections over 12 months. This is a 13 month study at the Porter Hospital Campus.

Wet AMD Naïve

Cedar AGN-150998 (Safety and Efficacy of Abicipar Pegol (AGN-150998) In Patients with Neovascular Age-Related Macular Degeneration) (Allergan)

In this study, patients will receive monthly intravitreal injections for 96 weeks. This is a 100 week study at Red Rocks Medical Center.

Stairway CR39521: Simultaneous Blockade Of Angiopoietin-2 And VEGF-A With The Bispecific Antibody RO6867461 (RG7716) For Extended Durability In The Treatment Of Neovascular Age-Related Macular Degeneration (Roche)

In this study, patients will receive monthly intravitreal injections up to week 12 followed by injections every 12 or 16 weeks.  This is a 12 month study consisting of 16 visits at the Red Rocks Medical Center.